(Q37354177)

19 August 2017

1 reference

title

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. (English)

1 reference

19 August 2017

Philippe Fournier

1

1 reference

19 August 2017

Volker Schirrmacher

series ordinal

2

1 reference

19 August 2017

publication date

1 January 2009

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

51-66

1 reference

An innate sense of danger

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth f

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Phase 2 trial of Allovectin-7 in advanced metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Development of the PANVAC-VF vaccine for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Anti-idiotype antibodies in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Immunotherapy as part of combinations for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.8.1.51

21 January 2018

Identifiers

DOI

10.1586/14760584.8.1.51

1 reference

19 August 2017

1 reference